DK3521312T3 - Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom - Google Patents

Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom Download PDF

Info

Publication number
DK3521312T3
DK3521312T3 DK19163475.7T DK19163475T DK3521312T3 DK 3521312 T3 DK3521312 T3 DK 3521312T3 DK 19163475 T DK19163475 T DK 19163475T DK 3521312 T3 DK3521312 T3 DK 3521312T3
Authority
DK
Denmark
Prior art keywords
periff
kir3dl2
treatment
binding specifically
compound binding
Prior art date
Application number
DK19163475.7T
Other languages
English (en)
Inventor
Cecile Bonnafous
Hélène Sicard
Renaud Buffet
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Application granted granted Critical
Publication of DK3521312T3 publication Critical patent/DK3521312T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK19163475.7T 2013-02-20 2014-02-20 Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom DK3521312T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361766798P 2013-02-20 2013-02-20
US201361831809P 2013-06-06 2013-06-06
EP14706017.2A EP2958941B1 (en) 2013-02-20 2014-02-20 A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma

Publications (1)

Publication Number Publication Date
DK3521312T3 true DK3521312T3 (da) 2021-06-28

Family

ID=50156759

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14706017.2T DK2958941T3 (da) 2013-02-20 2014-02-20 Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom
DK19163475.7T DK3521312T3 (da) 2013-02-20 2014-02-20 Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK14706017.2T DK2958941T3 (da) 2013-02-20 2014-02-20 Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom

Country Status (9)

Country Link
US (4) US20160002345A1 (da)
EP (3) EP3521312B1 (da)
JP (1) JP6360077B2 (da)
CN (1) CN105026427B (da)
AU (1) AU2014220668B2 (da)
CA (1) CA2899241C (da)
DK (2) DK2958941T3 (da)
ES (2) ES2730011T3 (da)
WO (1) WO2014128221A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
JP6507097B2 (ja) 2012-09-19 2019-04-24 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｋｉｒ３ｄｌ２結合剤
DK2958941T3 (da) 2013-02-20 2019-06-24 Innate Pharma Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom
US20160130346A1 (en) * 2013-05-29 2016-05-12 Institut National De La Sante Et De La Recherche Medicale Kir3dl2 is a biomarker and a therapeutic target useful for respectively preventing and treating a subset of cutaneous and non-cutaneous peripheral t-cell lymphomas
EP3019522B1 (en) 2013-07-10 2017-12-13 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
SG11201606789SA (en) * 2014-03-14 2016-09-29 Innate Pharma Humanized antibodies with increased stability
WO2016030488A1 (en) * 2014-08-27 2016-03-03 Innate Pharma Treatment of celiac disease
EP3307784B1 (en) * 2015-06-10 2021-12-22 National Research Council of Canada Carbonic anhydrase ix-specific antibodies and uses thereof
KR102554507B1 (ko) 2015-07-24 2023-07-11 이나뜨 파르마 에스.에이. 조직 침윤성 nk 세포를 검출하는 방법
CN109069664B (zh) 2016-01-27 2022-05-13 苏特罗生物制药公司 抗cd74抗体偶联物，包含抗cd74抗体偶联物的组合物以及抗cd74抗体偶联物的使用方法
KR20190008962A (ko) * 2016-06-02 2019-01-25 브리스톨-마이어스 스큅 컴퍼니 림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1 항체의 용도
JP2020500161A (ja) * 2016-10-21 2020-01-09 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 抗ｋｉｒ３ｄｌ２剤による処置
EP3658588A1 (en) * 2017-07-26 2020-06-03 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
CN108319816B (zh) * 2018-02-27 2021-04-23 广州大学 一种基于基因通路识别小分子核糖核酸的方法
WO2020152081A1 (en) 2019-01-22 2020-07-30 Innate Pharma Treatment of t cell lymphoma
AU2022255908A1 (en) * 2021-04-05 2023-10-05 Innate Pharma Immunohistochemistry methods and kir3dl2-specific reagents

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US5599790A (en) * 1992-06-11 1997-02-04 The Scripps Research Institute Fibrinogen γ chain polypeptide and compositions thereof
ATE365562T1 (de) 1996-05-03 2007-07-15 Immunomedics Inc Zielgerichtete kombinations-immuntherapie für krebs
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP2261229A3 (en) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
AP1775A (en) 1999-09-25 2007-08-28 Univ Iowa Res Found Immunostimulatory nucleic acids.
ATE556092T1 (de) 2000-12-18 2012-05-15 Inst Nat Sante Rech Med Mittel zur diagnose und therapie von ctcl
JP4359503B2 (ja) * 2001-08-23 2009-11-04 ゲンマブ エー／エス インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
JP2004126818A (ja) 2002-09-30 2004-04-22 Toshiba Corp 電子機器システム、電池ユニットおよび電池ユニットの動作制御方法
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
BRPI0412890B8 (pt) * 2003-07-24 2021-05-25 Innate Pharma método de selecionar um anticorpo anti kir2dl1 ou fragmento de anticorpo de ligação de antígeno
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
CA2563314A1 (en) 2004-04-16 2005-12-08 Macrogenics, Inc. Fcyriib-specific antibodies and methods of use thereof
KR101297146B1 (ko) 2004-05-10 2013-08-21 마크로제닉스, 인크. 인간화 ＦｃγＲＩＩＢ 특이적 항체 및 그의 사용 방법
DK2287195T3 (da) * 2004-07-01 2019-08-19 Innate Pharma Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi
WO2007024249A2 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
PT1836225E (pt) * 2005-01-06 2012-01-10 Novo Nordisk As Agentes de ligação a kir e métodos de utilização dos mesmos
AU2006255085A1 (en) 2005-06-03 2006-12-14 Genentech, Inc. Method of producing antibodies with modified fucosylation level
SI1919503T1 (sl) 2005-08-10 2015-02-27 Macrogenics, Inc. Identifikacija in inĺ˝eniring protiteles z variantnimi fc regijami in postopki za njih uporabo
FR2894982A1 (fr) 2005-12-16 2007-06-22 Lab Francais Du Fractionnement Procede de preparation d'anticorps selectifs des recepteurs fc activateurs
EP1977003A4 (en) 2005-12-22 2009-11-11 Dermagene Oy DISEASE-RELATED METHODS AND MEDIUM
MX2008009221A (es) 2006-01-17 2008-11-27 Biolex Therapeutics Inc Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas.
SG170110A1 (en) 2006-03-10 2011-04-29 Macrogenics Inc Identification and engineering of antibodies with variant heavy chains and methods of using same
CA2660592C (en) 2006-05-26 2016-07-12 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
CA2656224C (en) 2006-06-26 2018-01-09 Macrogenics, Inc. Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
MX2009003393A (es) * 2006-10-02 2009-05-11 Regeneron Pharma Anticuerpos humanos de alta afinidad para el receptor de il-4 humano.
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
US9181341B2 (en) * 2009-01-19 2015-11-10 Innate Pharma Anti-KIR3D antibodies
EP2454281B1 (en) * 2009-07-17 2018-11-14 Omeros Corporation Masp isoforms as inhibitors of complement activation
GEP20166442B (en) 2010-03-04 2016-03-10 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
JP2013533746A (ja) * 2010-07-06 2013-08-29 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｒｏｎ抗体
US10246510B2 (en) * 2012-09-19 2019-04-02 Innate Pharma KIR3DL2 binding agents
JP6507097B2 (ja) 2012-09-19 2019-04-24 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｋｉｒ３ｄｌ２結合剤
DK2958941T3 (da) 2013-02-20 2019-06-24 Innate Pharma Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom
US20160130346A1 (en) 2013-05-29 2016-05-12 Institut National De La Sante Et De La Recherche Medicale Kir3dl2 is a biomarker and a therapeutic target useful for respectively preventing and treating a subset of cutaneous and non-cutaneous peripheral t-cell lymphomas
SG11201606789SA (en) 2014-03-14 2016-09-29 Innate Pharma Humanized antibodies with increased stability
JP2020500161A (ja) 2016-10-21 2020-01-09 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 抗ｋｉｒ３ｄｌ２剤による処置

Also Published As

Publication number Publication date
AU2014220668A1 (en) 2015-08-20
US10174112B2 (en) 2019-01-08
EP3896088A1 (en) 2021-10-20
EP3521312B1 (en) 2021-04-07
EP2958941A1 (en) 2015-12-30
US11078275B2 (en) 2021-08-03
ES2878749T3 (es) 2021-11-19
JP6360077B2 (ja) 2018-07-18
EP2958941B1 (en) 2019-04-10
AU2014220668B2 (en) 2018-12-13
CN105026427B (zh) 2019-12-24
WO2014128221A1 (en) 2014-08-28
US20160002345A1 (en) 2016-01-07
CA2899241C (en) 2023-03-28
ES2730011T3 (es) 2019-11-07
EP3521312A1 (en) 2019-08-07
US20190127463A1 (en) 2019-05-02
CN105026427A (zh) 2015-11-04
CA2899241A1 (en) 2014-08-28
DK2958941T3 (da) 2019-06-24
US20210363248A1 (en) 2021-11-25
US20170298132A1 (en) 2017-10-19
JP2016513104A (ja) 2016-05-12

Similar Documents

Publication Publication Date Title
DK3521312T3 (da) Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom
DK3218406T3 (da) Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf
DK3003075T3 (da) Kit til inhalering af fordampede substanser
DK2895503T3 (da) Fibronektinbaserede skeletdomæneproteiner, der binder til myostatin
DK3090171T3 (da) Forbedringer relateret til komponenthåndtering, særligt vindmøllekomponenthåndtering
DK2897980T3 (da) Kir3dl2-bindemidler
DK3054976T3 (da) Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose
DK2970729T3 (da) Klæbemiddelsammensætning
BR112014016855A2 (pt) soluções aglutinantes
DK3350223T3 (da) Antistoffer, der binder specifikt til tl1a
DK2964258T3 (da) Antistoffer, der binder IL-23
DK3077346T3 (da) Bindemiddelsammensætning til forbedrede mørtler og belægninger
DK3027750T3 (da) Biokatalytisk sammensætning
DK2945968T3 (da) Antistoffer der binder til jagged 1
DK3052102T3 (da) Sammensætninger til behandling af cancere
DK3038656T3 (da) Forbindelse af glycosaminoglycan, fremgangsmåde til fremstilling og anvendelse deraf
DK3038633T3 (da) Stabile polypeptider der binder til human komplement c5
DK2999714T3 (da) Bindingsmolekyler som binder til human komplementfaktor C2 og anvendelser deraf
DK2951552T3 (da) Opfangningsanordning til engangsbrug
ZA201507808B (en) Binding element
FI10500U1 (fi) Kivisaha
ZA201505125B (en) Hydraulic binder
DK3052931T3 (da) Fremgangsmåde til overførsel af opslæmning
DK3071192T3 (da) Curcuphenolforbindelse til anvendelse i behandling af cancer
HK1218921A1 (zh) 特異性結合 的抗體